A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM
Eligible age
18–64 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is testing a new medicine that might help treat people with type 2 diabetes. The purpose of the study is to see if the new study medicine is safe and how well is tolerated by the body. There will be two groups of participants in this study: healthy participants and participants with type 2 diabetes. Participant will either get study medicine (NNC1679-0001) or placebo (a treatment that has no active medicine in it). NNC1679-0001 is a new experimental medicine that doctors cannot prescribe yet. Which treatment the participant gets is decided by chance. Participant will get one dose which will be injected into the area around abdomen (belly) by the medical staff.
Sponsor: Novo Nordisk A/S
You may qualify if…
- ✓ All participants
- ✓ Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study.
- ✓ Male or female (sex at birth) of nonchildbearing potential.
- ✓ Age 18-64 years (both inclusive) at the time of signing the informed consent.
- ✓ Healthy participants
- ✓ Body mass index (BMI) 18.5-29.9 kilograms per square meter (kg/m\^2) (both inclusive) at screening.
- ✓ Glycated haemoglobin (HbA1c) lesser than or equal to (\<=) 6.4 percent (%) (47 \[millimoles per mole\] mmol/mol) at screening.
- ✓ Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiograms (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.
You may not qualify if…
- ✕ All participants
- ✕ Screening alanine aminotransferase (ALT) values greater than (\>) upper limit of normal (ULN) +10%, aspartate aminotransferase (AST) values \>ULN +20%, or total bilirubin \>ULN.
- ✕ Renal impairment, defined as estimated glomerular filtration rate (eGFR) \<60.0 milliliter per minute per 1.73 square meter (mL/min/1.73m\^2), at screening.
- ✕ Clinical evidence of chronic kidney disease (CKD) and/or urinary albumin: creatinine ratio (UACR) \>30 milligrams per gram (mg/g).
- ✕ Presence or history of cardiovascular disease, including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, or clinically significant conduction disorders.
- ✕ Healthy participants
- ✕ Any disorder that, in the investigator's opinion, might jeopardise participants' safety or compliance with the protocol.
- ✕ Supine blood pressure at screening outside the range of 90-139 millimeters of mercury (mmHg) for systolic or 50-89 mmHg for diastolic.
Source: ClinicalTrials.gov · NCT07570992 · last updated 2026-06-22